Table 1.
Patient characteristics of the intention-to-treat population
| Characteristic | Pre-emptive Group (n=36) | Valacyclovir Group (n=34) | P Value |
|---|---|---|---|
| Recipient | |||
| age (yr) | 50±13 | 48±12 | 0.51 |
| men | 28 (78) | 27 (79) | 1.0 |
| previous transplantation | 3 (8) | 4 (12) | 0.71 |
| HLA mismatches (n) | 3.6±1.2 | 3.5±1.2 | 0.77 |
| CMV serostatus | 0.62 | ||
| D+/R− | 6 (17) | 4 (12) | |
| D+/R+ | 23 (64) | 24 (71) | |
| D−/R+ | 7 (19) | 6 (18) | |
| Donor | |||
| age (yr) | 43±16 | 47±14 | 0.25 |
| donor type (deceased) | 34 (94) | 34 (100) | 0.49 |
| expanded-criteria donora | 10 (29) | 11 (32) | 1.0 |
| donation after cardiac death | 2 (6) | 2 (6) | 1.0 |
| Primary immunosuppression | 0.54 | ||
| cyclosporine + mycophenolate mofetil | 25 (69) | 23 (68) | |
| tacrolimus + mycophenolate mofetil | 6 (17) | 5 (15) | |
| sirolimus + mycophenolate mofetil | 5 (14) | 6 (18) | |
| basiliximab | 5 (14) | 7 (21) | |
| rATG induction | 4 (11) | 5 (15) |
For detailed characteristics, see reference 16. Data are number of patients (percentage) or mean ± SD. rATG, rabbit antithymocyte globulin.
a
According to the United Network for Organ Sharing criteria.